Gilead Sciences Inc (GILD) - Total Assets
Based on the latest financial reports, Gilead Sciences Inc (GILD) holds total assets worth $59.02 Billion USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore GILD operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Gilead Sciences Inc - Total Assets Trend (1990–2024)
This chart illustrates how Gilead Sciences Inc's total assets have evolved over time, based on quarterly financial data. See Gilead Sciences Inc shareholders equity for net asset value and shareholders' equity analysis.
Gilead Sciences Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Gilead Sciences Inc's total assets of $59.02 Billion consist of 32.5% current assets and 67.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 16.9% |
| Accounts Receivable | $4.42 Billion | 7.5% |
| Inventory | $1.71 Billion | 2.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $19.95 Billion | 33.8% |
| Goodwill | $8.31 Billion | 14.1% |
Asset Composition Trend (1990–2024)
This chart illustrates how Gilead Sciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Gilead Sciences Inc (GILD) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Gilead Sciences Inc's current assets represent 32.5% of total assets in 2024, a decrease from 83.2% in 1990.
- Cash Position: Cash and equivalents constituted 16.9% of total assets in 2024, down from 82.4% in 1990.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 47.0% of total assets, an increase from 0.0% in 1990.
- Asset Diversification: The largest asset category is intangible assets at 33.8% of total assets.
Gilead Sciences Inc Competitors by Total Assets
Key competitors of Gilead Sciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$207.62 Billion |
|
AstraZeneca PLC
NYSE:AZN
|
USA | $114.02 Billion |
|
AstraZeneca PLC
NASDAQ:AZN
|
USA | $114.02 Billion |
|
Organon & Co
NYSE:OGN
|
USA | $13.00 Billion |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
|
Brazil | R$3.66 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$2.28 Million |
|
Eli Lilly and Company
SA:LILY34
|
Brazil | R$112.48 Billion |
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SHG:600436
|
China | CN¥18.38 Billion |
Gilead Sciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.68 | 1.60 | 1.37 |
| Quick Ratio | 1.31 | 1.45 | 1.18 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $8.07 Billion | $7.17 Billion | $3.57 Billion |
Gilead Sciences Inc - Advanced Valuation Insights
This section examines the relationship between Gilead Sciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.48 |
| Latest Market Cap to Assets Ratio | 2.74 |
| Asset Growth Rate (YoY) | -5.0% |
| Total Assets | $58.99 Billion |
| Market Capitalization | $161.55 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Gilead Sciences Inc's assets at a significant premium (2.74x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Gilead Sciences Inc's assets decreased by 5.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Gilead Sciences Inc (1990–2024)
The table below shows the annual total assets of Gilead Sciences Inc from 1990 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $58.99 Billion | -5.04% |
| 2023-12-31 | $62.12 Billion | -1.66% |
| 2022-12-31 | $63.17 Billion | -7.04% |
| 2021-12-31 | $67.95 Billion | -0.67% |
| 2020-12-31 | $68.41 Billion | +11.00% |
| 2019-12-31 | $61.63 Billion | -3.22% |
| 2018-12-31 | $63.67 Billion | -9.40% |
| 2017-12-31 | $70.28 Billion | +23.35% |
| 2016-12-31 | $56.98 Billion | +9.91% |
| 2015-12-31 | $51.84 Billion | +49.55% |
| 2014-12-31 | $34.66 Billion | +53.52% |
| 2013-12-31 | $22.58 Billion | +6.30% |
| 2012-12-31 | $21.24 Billion | +22.75% |
| 2011-12-31 | $17.30 Billion | +49.26% |
| 2010-12-31 | $11.59 Billion | +19.53% |
| 2009-12-31 | $9.70 Billion | +39.81% |
| 2008-12-31 | $6.94 Billion | +18.89% |
| 2007-12-31 | $5.83 Billion | +42.80% |
| 2006-12-31 | $4.09 Billion | +8.49% |
| 2005-12-31 | $3.77 Billion | +74.69% |
| 2004-12-31 | $2.16 Billion | +38.67% |
| 2003-12-31 | $1.55 Billion | +20.69% |
| 2002-12-31 | $1.29 Billion | +62.08% |
| 2001-12-31 | $794.79 Million | +17.21% |
| 2000-12-31 | $678.10 Million | +55.24% |
| 1999-12-31 | $436.81 Million | -10.45% |
| 1998-12-31 | $487.80 Million | +38.54% |
| 1997-12-31 | $352.10 Million | +13.32% |
| 1996-12-31 | $310.70 Million | +86.38% |
| 1995-12-31 | $166.70 Million | +62.79% |
| 1994-12-31 | $102.40 Million | -19.12% |
| 1993-12-31 | $126.60 Million | -13.76% |
| 1992-12-31 | $146.80 Million | +35.05% |
| 1991-12-31 | $108.70 Million | +769.60% |
| 1990-12-31 | $12.50 Million | -- |
About Gilead Sciences Inc
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the t… Read more